66 results on '"Villamor N"'
Search Results
2. P1277: MUTATIONAL LANDSCAPE AND COPY NUMBER ALTERATIONS IN TESTICULAR LARGE B-CELL LYMPHOMA
3. TESTICULAR DIFFUSE LARGE B‐CELL LYMPHOMA: CLINICO‐BIOLOGICAL CHARACTERIZATION, EVALUATION OF TREATMENT RESPONSE AND SURVIVAL
4. Is chronic lymphocytic leukemia curable? A clinical case relapsing 21 years after allogeneic stem-cell transplantation
5. SP469STUDY OF BIOCOMPATIBILITY OF MEMBRANES IN HEMODIAFILTRACIÓN ON-LINE
6. MUTATIONAL LANDSCAPE OF DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) AT DIAGNOSIS AND AT PROGRESSION ASSESSED BY CIRCULATING TUMOR DNA ANALYSIS
7. MUTATIONAL LANDSCAPE OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS
8. PS1323 HIGH SERUM LEVELS OF IL‐2R, IL‐6 AND TNF ARE ASSOCIATED WITH HIGHER TUMOR BURDEN AND POORER OUTCOME IN PATIENTS WITH NEWLY DIAGNOSED FOLLICULAR LYMPHOMA
9. PF522 MUTATIONAL LANDSCAPE OF PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS
10. PATTERNS OF CHANGE IN TREATMENT, SURVIVAL, HISTOLOGICAL TRANSFORMATION, AND SECONDARY MALIGNANCIES OF FOLLICULAR LYMPHOMA OVER THE LAST 4 DECADES: A SINGLE CENTER EXPERIENCE
11. PS1144 TARGETING IRAK4 DISRUPTS INFLAMMATORY PATHWAYS AND DELAYS TUMOR DEVELOPMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA
12. GENOTYPING PRIMARY MEDIASTINAL B-CELL LYMPHOMA (PMBCL) BY MEANS OF CIRCULATING TUMOR DNA ANALYSIS
13. Clinicobiological features and prognostic impact of diffuse large B-cell lymphoma component in the outcome of patients with previously untreated follicular lymphoma
14. Clinical impact of the subclonal architecture and mutational complexity in chronic lymphocytic leukemia
15. Progression-free survival shortens after each relapse in patients with follicular lymphoma treated in the rituximab era
16. The addition of ofatumumab to the conditioning regimen does not improve the outcome of patients with high-risk CLL undergoing reduced intensity allogeneic haematopoietic cell transplantation: a pilot trial from the GETH and GELLC (CLL4 trial)
17. Survival analysis in hematologic malignancies: recommendations for clinicians
18. A B-cell epigenetic signature defines three biologic subgroups of chronic lymphocytic leukemia with clinical impact
19. Genomic complexity and IGHV mutational status are key predictors of outcome of chronic lymphocytic leukemia patients with TP53 disruption
20. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model
21. The γ-secretase inhibitor PF-03084014 combined with fludarabine antagonizes migration, invasion and angiogenesis in NOTCH1-mutated CLL cells
22. The prognostic impact of minimal residual disease in patients with chronic lymphocytic leukemia requiring first-line therapy
23. Chronic lymphocytic leukemia in young individuals revisited
24. The phosphatidylinositol-3-kinase inhibitor NVP-BKM120 overcomes resistance signals derived from microenvironment by regulating the Akt/FoxO3a/Bim axis in chronic lymphocytic leukemia cells
25. NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome
26. Sorafenib targets BCR kinases and blocks migratory and microenvironmental survival signals in CLL cells
27. 4.25 Update on the International Standardized Approach for Flow Cytometric Residual Disease Monitoring in CLL
28. Immunophenotype of acute myeloid leukemia with NPM mutations: Prognostic impact of the leukemic compartment size
29. Comparison of four prognostic scores in peripheral T-cell lymphoma
30. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior
31. Expanded and highly active proliferation centers identify a histological subtype of chronic lymphocytic leukemia ("accelerated" chronic lymphocytic leukemia) with aggressive clinical behavior
32. 9217 DNA reparation genes in genetic and epigenetic susceptibility to Chronic Lymphocytic Leukaemia
33. Harms and benefits of lymphocyte subpopulations in patients with acute stroke
34. Identification of TIGAR in the equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells
35. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells
36. Gene expression profile and genomic changes in disease progression of early-stage chronic lymphocytic leukemia
37. Induction of histone H1.2 cytosolic release in chronic lymphocytic leukemia cells after genotoxic and non-genotoxic treatment
38. Central nervous system involvement in mantle cell lymphoma
39. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia
40. The Follicular Lymphoma International Prognostic Index (FLIPI) and the histological subtype are the most important factors to predict histological transformation in follicular lymphoma
41. Combination Chemotherapy with Fludarabine, Cyclophosphamide and Mitoxantrone (FCM) Induces a High Response Rate in Previously Untreated CLL.
42. Adverse prognostic impact of CD36 and CD2 expression in adult de novo acute myeloid leukemia patients
43. International Standardized Approach to Molecular and Flow Cytometric Residual Disease Monitoring in CLL.
44. Equilibrative nucleoside transporter-2 (hENT2) protein expression correlates with ex vivo sensitivity to fludarabine in chronic lymphocytic leukemia (CLL) cells
45. Simultaneous diagnosis of hairy cell leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma: a frequent association?
46. Bladder Involvement of Diffuse Large B-cell Lymphoma Diagnosed by a Cytological Study of the Urine
47. Stem cell transplantation for chronic lymphocytic leukemia: different outcome after autologous and allogeneic transplantation and correlation with minimal residual disease status
48. FISH analysis for BCL-1 rearrangements and trisomy 12 helps the diagnosis of atypical B cell leukaemias
49. Anaplastic large-cell lymphoma with rapid evolution to leukemic phase
50. Identification of a natural soluble form of human CD5
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.